In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr. Reddy's Biosimilar Ambition

Executive Summary

India-based drug makers, who have built themselves into regional powerhouses thanks to their efforts in creating small molecules generics, are keenly interested in the biosimilar opportunity. But none has been as aggressive-or as brash - as Dr. Reddy's Laboratories. (This is a sidebar to the article "Opening A Door To Biosimilars In the US."

You may also be interested in...



Opening A Door To Biosimilars In The US

With the regulatory door ajar, companies across the pharmaceutical industry are vying to dominate the biosimilars space, despite the commercial risks.

Vitamin D No ‘Magic Bullet’ Against COVID-19, But Should Be Part Of Nutrition Arsenal

Researchers say “no strong” evidence shows high vitamin D intake is beneficial to preventing or treating COVID-19, but adequate levels are needed to support immunity. Other researchers say countries should increase recommended vitamin D levels with “very suggestive” evidence supporting its effect against COVID-19 severity.

Tech Transfer Roundup: Inside The Law That Transformed The Research Landscape

The Bayh-Dole act of 1980 facilitated deal-making between private-sector firms and research institutions, largely seeding the US biotech industry. Plus, an overview of the latest tech transfer deals.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL021506

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel